Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Updated cash guidance provides runway into at least mid-2026

MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA^® at medical conferences and a planned KOL event

Read more at globenewswire.com